This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Edwards-JenaValve deal 'soars over the bar set by Congress,' US FTC argues

( October 23, 2025, 23:00 GMT | Official Statement) -- MLex Summary: Edwards Lifesciences' proposed acquisition of JenaValve Technology is a brazen violation of America's cornerstone merger control law, the Clayton Act, the US Federal Trade Commission said in a memo supporting its motion for a preliminary injunction. "Though a merger to 100% market share is not required to run afoul of Section 7, there is no doubt that this case soars over the bar set by Congress," the FTC wrote. "By combining the only two TAVR AR device companies currently in U.S. clinical trials, the Proposed Transaction not only tends to create a monopoly—it does, in fact, create a monopoly."See attached document. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login